Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Fuji
Cantor Fitzgerald
Moodys
UBS
Teva

Generated: September 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,855,388

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,855,388 protect, and when does it expire?

Patent 9,855,388 protects ADLYXIN and is included in one NDA.

This patent has twenty patent family members in sixteen countries.

Summary for Patent: 9,855,388
Title:Dosing and drive mechanism for drug delivery device
Abstract: The present invention relates to drive mechanisms suitable for use in drug delivery devices, in particular pen-type injectors, wherein a number of pre-set doses of medicinal product can be administered. In particular, the present invention relates to such drug delivery devices where a user may activate the drug delivery device.
Inventor(s): Boyd; Malcolm (Leamington Spa, GB), Letham; Richard (Surrey, GB), Plumptre; David (Worcestershire, GB), Veasey; Robert (Warwickshire, GB), May; James (Coventry, GB), Jones; Matthew (Warwickshire, GB), Ghazaros; Samuel (Bristol, GB)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE)
Application Number:14/542,230
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Delivery; Device; Dosage form;

Drugs Protected by US Patent 9,855,388

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-001 Jul 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR ➤ Sign Up
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-002 Jul 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,855,388

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06023961Nov 17, 2006

International Family Members for US Patent 9,855,388

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 063838 ➤ Sign Up
Australia 2007321446 ➤ Sign Up
Brazil PI0719009 ➤ Sign Up
Canada 2669363 ➤ Sign Up
China 101616705 ➤ Sign Up
European Patent Office 1923085 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Julphar
Citi
Chubb
UBS
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.